FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$31.32

17 May
2021

0.640

OPEN

$30.98

2.09%

HIGH

$31.51

529,242

LOW

$30.75

TARGET
$33.50 7.0% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . RAP . RVA . MEB . IME . AHX . PCK . CMP . CYC . IMR . VTI . OVN . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY21
Forecast		 FY22
Forecast
EPS (cps) 95.7 xxx
DPS (cps) 44.6 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 32.0 xxx
Dividend Yield 1.5% xxx
Div Pay Ratio(%) 46.6% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 2.30%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.90

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/12 - 16c (0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx47.5
DPS All xxxxxxxxxxxxxxx30.7
Sales/Revenue xxxxxxxxxxxxxxx1,210.0 M
Book Value Per Share xxxxxxxxxxxxxxx164.2
Net Operating Cash Flow xxxxxxxxxxxxxxx305.4 M
Net Profit Margin xxxxxxxxxxxxxxx22.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

5

xxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

20/04/2021

1

Resume Coverage with Outperform

$33.50

6.96%

Credit Suisse resumes coverage with an Outperform rating and $33.50 target. A strong outlook is underpinned by a quality core hospital business, the broker suggests, with an US$11bn opportunity to expand the nasal high-flow therapy into adjacent settings.

Post the pandemic, the broker forecasts double-digit earnings growth over the medium term. Credit Suisse assesses the nasal high flow and invasive ventilation installed base has increased by more than 50% over FY21.

FORECAST
Credit Suisse forecasts a full year FY21 dividend of 46.55 cents and EPS of 94.03 cents.
Credit Suisse forecasts a full year FY22 dividend of 47.48 cents and EPS of 67.03 cents.

Citi

xx/xx/xxxx

5

xxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

FPH STOCK CHART

FNArena News on FPH

1
Australian Broker Call *Extra* Edition – May 05, 2021

May 05 2021 - Daily Market Reports
2
New Product, Patient Growth Key To ResMed

May 03 2021 - Australia
3
Australian Broker Call *Extra* Edition – Apr 15, 2021

Apr 15 2021 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Mar 31, 2021

Mar 31 2021 - Daily Market Reports
5
Investment Strategies For A Global Recovery

Mar 29 2021 - International

Latest Medical Equipment & Devices News

1
Treasure Chest: How Much Covid Impact For Nanosonics?

May 13 2021 - Treasure Chest
2
Who Will Be The Next Pro Medicus?

May 13 2021 - Weekly Reports
3
New Product, Patient Growth Key To ResMed

May 03 2021 - Australia
4
Growth For ResMed Despite Challenges

Feb 01 2021 - Australia
5
Short-Term Risks Remain For Nanosonics

Nov 05 2020 - Australia
6
Home Health The Way Forward For ResMed

Nov 02 2020 - Australia
7
Treasure Chest: Cochlear Advancing

Oct 27 2020 - Treasure Chest
8
Cochlear On The Mend But Recovery Unclear

Oct 21 2020 - Australia
9
ResMed Wakes Up

Oct 13 2020 - Technicals
10
Nanosonics’ Delay Frustrates Investors

Aug 26 2020 - Australia